Immunyx Pharma is focused on changing the landscape of immune modulation by targeting neutrophil toxicity in numerous chronic diseases. The company was built by world leaders in neutrophil biology and nanoparticle delivery to use a targeted neutrophil nanoparticle platform (TENNs) to solve the significant issues in neutrophil therapy. While big pharma has invested heavily in neutrophil targeted drugs, they have failed to bring solutions to the clinic due to the danger of causing neutropenia and the difficulty of modulating such a large & dynamic population of cells. Our TENN platform is intended to manipulate neutrophil toxic behavior without destroying their disease fighting function, while bringing a concentrated payload of drug to all neutrophils throughout the body with a long bioavailability. We are currently focusing on applying our platform to modulate neutrophil activity in cancer and inflammatory disease.
Company Details
- Employees
- 8
- Founded
- -
- Address
- New York, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.immunyx.com
- HQ
- New York, NY
Immunyx Pharma Questions
Immunyx Pharma's website is http://www.immunyx.com
Immunyx Pharma's LinkedIn profile is https://www.linkedin.com/company/immunyx-pharma
Immunyx Pharma has
8 employees.
View email and phone details for 8
employees at Immunyx Pharma.
Immunyx Pharma's industry is
Biotechnology Research
Immunyx Pharma's top competitors are
Vlx Ventures,
Castlevax,
Akagera Medicines, Inc,
Everly Bio,
Point6 Bio,
Neuroene Therapeutics,
Sakura Bio,
Aion Labs,
Protica Bio,
Curesponse.
Immunyx Pharma's categories are Biotechnology Research
Immunyx Pharma's founding year is 2021
